Sage Journals: Discover world-class research

Abstract

IgG4-related systemic disease is a recently recognized systemic condition characterized by unique pathological features that can affect a variety of organs. It includes a growing number of medical conditions which have the following features in common: diffuse organ swelling or focal mass formation, sclerosing storiforme (whirl-shaped) fibrosis with a lymphoplasmacytic infiltrate rich in IgG4-bearing plasma cells, as well as elevated levels of serum IgG4. It invariably responds to steroid treatment and is mostly diagnosed in elderly men. Well-known syndromes like Mikulicz's disease of the salivary or lacrimal gland, Küttner's tumour of the submandibular gland, Riedel's thyroiditis, or retroperitoneal fibrosis, as well as novel entities such as autoimmune pancreatitis type 1, are now regarded to be manifestations of this systemic disease. This article provides an overview of the epidemiology, concepts of pathogenesis, clinical presentation, proposed diagnostic approaches, treatment options, and differential diagnosis of IgG4-related disease.

Keywords

Autoimmune pancreatitis type 1 IgG4-related syndrome Mikulicz's disease sclerosing cholangitis

Introduction

IgG4-related disease or IgG4-related syndrome is a recently recognized entity that includes a number of already established conditions as well as novel entities which are now understood to be part of a systemic syndrome. All are characterized by diffuse organ swelling or mass formation and distinct histopathological features that can occur in multiple organs either simultaneously or subsequently and which include an abundance of lymphoplasmacytic infiltrates, IgG4-positive plasma cells and fibrosis. Furthermore, IgG4-positive plasma cells can even be found in primarily unaffected organs and serum IgG4 levels are often elevated. The organ manifestation which is probably best characterized is autoimmune pancreatitis (AIP) type 1. As early as 2003, Kamisawa et al. reported an extrapancreatic involvement in a series of cases with AIP.¹ To date, involvement of the central nervous system, the periorbital tissue, breast, pericardium, lacrimal/salivary glands, thyroid gland, lungs, pancreas, biliary duct, liver, gastrointestinal tracts, kidneys, prostate gland, retroperitoneum, skin, arteries, and lymph nodes^2,3 has been described and the list is constantly growing (Table 1). Although it is regarded to be a rare disease in conjunction with AIP, IgG4-related systemic disease has probably been underdiagnosed in the past due to poor awareness among healthcare providers and only recently has recognition grown among a variety of specialists. Epidemiological data, however, remain insufficient. Two Japanese studies based on hospital data estimated a prevalence of roughly 100 per 1,000,000 population and an annual incidence of 1:100,000.^4,5 These studies further suggest that men are about twice as likely to develop IgG4-related disease and most patients are between 50 and 70 years of age at the time of diagnosis. Hardly any patient is younger than 40 years, which poses the diagnostic challenge of not confusing IgG4-related masses with malignant lesions.

Table 1.

Previously recognized conditions that are part of IgG4-related disease

Previous name	Affected organ	Reference
Mikulicz's disease	Salivary and lacrimal gland	Yamamoto et al.²⁸
Küttner's tumour	Submandibular gland	Geyer et al.²⁹
Riedel's thyroiditis	Thyroid	Dahlgren et al.³⁰
Chronic sclerosing aortitis	Aorta	Stone et al.³¹
Morbus Ormond	Retroperitoneum	Hamano et al.³²
Autoimmune pancreatitis	Pancreas	Hamano et al.³³
Sclerosing cholangitis	Biliary system	Ghazale et al.³⁴
Orbital pseudotumour	Orbita	Cheuk et al.³⁵
Autoimmune hepatitis	Liver	Yada et al.²⁶
Multifocal fibrosclerosis	Multiple organs	Kamisawa et al.¹

Pathogenesis of IgG4-related disease

As IgG4 has lent its name to this group of diseases it is appropriate to focus on pathological aspects of IgG4. IgG4 is a remarkable immunoglobulin in both structure and function. IgG4 accounts for less than 5% of the total IgG and it function differs from that of other IgG subclasses. Amino acid differences in the second constant domain of IgG4 lead to weak or negligible binding of IgG4 to both C1q and Fcc receptors. As a consequence, IgG4 does not activate the classical complement pathway and therefore plays a limited role in activation of the immune system.⁶ Another peculiarity of IgG4 molecules is the so-called Fab-arm exchange. Disulphide bonds between the heavy chains of the molecule are weaker than in other IgG subclasses, leading to dissociation and random recombination under certain circumstances. The result is a variety of bivalent or ‘functionally monovalent’ antibodies which are unable to crosslink antigens, thereby losing the ability to form immune complexes⁷. Noteworthy, IgG4 is able to bind the constant domain of other IgGs which allows it to act as an inactive rheumatoid factor and thus might contribute to its anti-inflammatory properties.

IgG4 production can physiologically be induced by sustained or repeated antigen exposure and, similar to IgE production, the production is predominantly induced by type 2 T-helper cells. To our current understanding, a Th2 immune reaction with activation of regulatory T-cells (T-regs) producing transforming growth factor β and interleukin 10 favours IgG4 production.⁸ Several autoantibodies have been identified in patients with IgG4-related syndrome. Although none of them seem to be disease specific or diagnostic, they could be related to common target structures in affected organs. Antibodies specific for lactoferrin, carbonic anhydrase II and IV, pancreatic secretory trypsin inhibitor (PSTI or SPINK1), amylase, heat shock protein 10, and plasminogen-binding protein have been detected, predominantly of the IgG type 1.⁹ One concept for the eventual breakdown of immune tolerance is molecular mimicry. Pathogens share common epitopes with their host and can therefore initiate a sustained auto-inflammatory stimulus: e.g. carbonic anhydrase II and plasminogen-binding protein of Helicobacter pylori show homologies with human proteins.⁹

The presence of T- and B-cells in the lymphplasmacytic infiltrate of affected organs, the presence of autoantibodies and the abundance of IgG4 producing plasma cells suggest an immunologically mediated pathomechanism. Okazaki et al. proposed a two-step process for the development of IgG4-related disease.⁹ Briefly, molecular mimicry and genetic predisposition lead to an initial Th1-dominated immune response against self-antigens and the initiation of tissue damage, which is aggravated by a lack of naïve circulating T-regs. The persistent presence of triggering pathogens maintains activation of the immune system which eventually induces a Th2 and peripheral T-reg response, favouring IgG4 production and fibrosis, the latter leading to disease progression (Figure 1).

Figure 1.

Pathogenesis of IgG4-related disease.

Clinical presentation

With regard to the variety of disease manifestations and for the purpose of this review, we would like to focus on manifestations of IgG4-related disease within the gastrointestinal tract such as AIP type 1 as well as IgG4-associated sclerosing cholangitis. Patients with IgG4-related disease present with diffuse organ swelling or a focal mass formation which leads to either a pseudotumour or nodular organ swelling. The disease can affect multiple organs simultaneously or consecutively, including conditions which have previously been looked at as unique clinical entities (Table 1). The disease usually develops subacutely and most patients feel only moderately ill. Levels of total serum IgG are usually elevated and IgG4 levels more than 25-times above the upper limit of normal have been reported.¹⁰ However, elevation of serum IgG4 over 2- or 3-times the upper limit of normal are generally considered to be specific and diagnostic for AIP.^11–17 Other inflammatory serum markers are only moderately elevated and a clinical presentation with weight loss or fever is rather uncommon.³ About half of the cases present with elevated IgE levels and peripheral blood eosinophilia.¹⁸ Although it has been reported that 74% of cases with AIP type I would undergo spontaneous remission,¹⁹ untreated IgG4-related disease often causes major damage to affected organs, leading eventually to organ dysfunction.²⁰

The appearance of AIP on imaging has elsewhere been discussed at length.^12,14,15 Briefly, the pancreas presents as either generally enlarged giving rise to a so-called ‘sausage-shaped pancreas’ or with a focal mass. These masses often present with a hypodense rim, indicating delayed uptake of contrast enhancers. The pancreatic duct is characterized by calibre irregularities and long stretch narrowing without significant distal dilatation.^21–23 The biliary tract is the most frequent site of extrapancreatic involvement of AIP or may occur as a separate entity, then called IgG4-related sclerosing cholangitis. It is best characterized on endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography, but also computed tomography or endoscopic ultrasound can reveal typical features such as concentric mural thickening and segmental or long ductal narrowing with and without prestenotic dilatation (Figure 2). Again, the affected soft tissue shows delayed contrast enhancement. IgG4-related cholangitis is subclassified in four different types, depending on the location of the predominant stricture:²⁴ type 1, located only in the lower part of the common bile duct; type 2, diffusely distributed in the intra- and extrahepatic bile ducts; type 3, stenosis in both the hilar intrahepatic ducts and the lower part of the common bile duct; and type 4, located only in the hilum. Type 2 IgG4-related cholangitis can mimic a group of other pancreaticobiliary disorders on imaging such as pancreatic cancer, primary sclerosing cholangitis, and cholangiocarcinoma²⁵ and patients frequently present with obstructive jaundice. IgG4-related autoimmune hepatitis can be found in 3.3% of patients previously diagnosed with classical autoimmune hepatitis.^26,27 The diagnosis is made in the absence of antimitochondrial, antismooth muscle, and liver kidney microsomal antibodies. Interestingly, 50% of patients with IgG4-related autoimmune hepatitis suffer from acalculous sclerosing cholecystitis. However, therapeutically IgG4-related autoimmune hepatitis is often overlooked because treatment is not different from classical autoimmune hepatitis and symptoms usually respond quickly to steroid treatment.

Figure 2.

Typical case of IgG4-related sclerosing cholangitis.

About one-third of patients with IgG4-related syndrome present with tubulo-interstitial nephritis.⁷ Lesions are hypoattenuating on computed tomography, show late phase enhancement, and will be iso- or hypointense on T1 and hyperintense on T2-weighted MRI. Cortical, pelvic, and diffuse lesions have been described and are usually present bilaterally and at multiple sites.²⁵ Similarly, involvement of salivary and lacrimal glands will appear bilaterally as enlarged and homogenous masses. Conditions like chronic sclerosing sialadenitis (Küttner's disease), chronic dacryoadenitis, and Mikulicz's disease as well as Riedel's thyroiditis are now considered manifestations of the IgG4-related syndrome. Retroperitoneal fibrosis (also referred to as morbus Ormond, Ormond's disease) and vascular disease includes similar imaging features, with MRI appearance depending on the current activity of inflammation and oedema. Pulmonary involvement can appear as nodular or focal mass, thickened bronchovascular bundles, air trapping, and mediastinal involvement. Lymphadenopathy is a common feature of IgG4-related disease and can go along with any organ involvement. Nodules are enlarged, with homogenous enhancement and no calcification or necrosis.²⁵

Histological features

The recognition of distinct histopathological features in a variety of previously independent conditions has finally led to the concept of a systemic IgG4-related disease. The key findings are:

dense lymphoplasmacytic infiltrate with storiform (whirl-shaped) fibrosis

obliterative phlebitis

abundance of IgG4-bearing plasma cells.

The abundance of IgG4-positive plasma cells is a necessary but not sufficient criterion for the diagnosis of IgG4-related disease. Numbers of more than 10 IgG4-positive cells per high power field and a ratio of IgG4-positive cells to all IgG-bearing cells >40–50% are highly suggestive.^5,17,36 Neutrophils are not a common feature and, although the infiltrate tends to aggregate around the ducts of glandular organs, no direct ductal infiltration is seen. B-cells form typical germinal centres, whereas T-cells will be found in a more scattered pattern. Granulomas are uncommon.⁷ Histopathological analysis of affected organs remains the gold standard for the diagnosis of IgG4-related disease.

Diagnostic criteria

The Japanese IgG4-related disease study group has recently published a diagnostic guideline for IgG4-related disease,^2,37 which allows a comprehensive approach, fully aware that the clinical presentation can be very variable depending on the site of manifestation (Table 2). The proposed guidelines include three criteria: characteristic diffuse swelling or organ mass, increased serum IgG4 levels of greater than 135 mg/dl and a positive histology. With all three criteria being positive, the definitive diagnosis can be made. With negative histology or histology not performed, the diagnosis is ‘possible IgG4-related disease’, and with positive histology but no elevated serum markers, the diagnosis is ‘probable IgG4-related disease’ (Figure 3). This classification showed satisfactory sensitivity for possible IgG4-related disease when retrospectively applied to cohorts with proven IgG4-related Mikulicz's disease, kidney disease, or AIP type 1. Thus it can be applied in clinical practice to justify further diagnostic work up when the suspicion of an IgG4-related disease arises. Organ-specific guidelines as published for Mikulicz's disease or AIP should be used in addition.^2,12,37 Problems might occur due to the fact, that for the definite diagnosis histology is required which often is difficult to obtain (e.g. from the retroperitoneum, the orbita, or the pancreas). In addition, it is noteworthy that the International Consensus Diagnostic Criteria for AIP consider as diagnostic an IgG4 level more than twice the level of normal.^11,12

Figure 3.

Diagnostic algorithm for IgG4-related disease.

Table 2.

Comprehensive diagnostic criteria for IgG4-related disease

Diagnosis	Criteria
Definitive	Diffuse or local swelling in single or multiple organs
	Serum IgG4 levels ≥135 mg/dl
	Histology
	Lymphoplasmacytic infiltrate and fibrosis
	IgG4-positive plasma cells: ratio of IgG4/IgG positive cells >40%, and >10 IgG4-positive plasma cells/high power field
Probable	Diffuse or local swelling in single or multiple organs
	Histology
	Lymphoplasmacytic infiltrate and fibrosis
	IgG4-positive plasma cells: ratio of IgG4/IgG positive cells >40% and >10 IgG4-positive plasma cells/high power field
Possible	Diffuse or local swelling in single or multiple organs
	Serum IgG4 levels ≥135 mg/dl or >2-fold upper limit of normal

Source: Okazaki et al.²

It is important to note that other conditions such as lymphoma, Sjögren's disease, primary sclerosing cholangitis, multicentric Castleman's disease (rare lymphoproliferative disorder unrelated to IgG4 disease), inflammatory bowel disease, and different cancers will also partially fulfil the diagnostic criteria of IgG4-related disease.^2,38 Therefore diagnostic work up to exclude diseases other than IgG4-related disease is mandatory and disease-specific guidelines should be followed. Since malignant lymphoma can improve under administration of steroids, a steroid trial to establish the diagnosis of IgG4-related disease should be avoided when lymphoma is a differential diagnosis, except for AIP type 1 where a steroid trial can be necessary to confirm the diagnosis in a minority of cases, according to international guidelines.^37,39 Exclusion of malignancy is generally warranted in these patients but can be difficult and can often only be achieved by histological sampling of the affected tissue.

Treatment

IgG4-related disease responds rapidly to steroid treatment with a nearly 100% initial response rate.^19,20 Relapse is not a rare event (up to 47%), based on data from AIP patients.^20,40 Treatment protocols vary in accordance to local standards. While groups from the USA favour a 4-week course of 40–80 mg prednisolon per day,⁴¹ followed by steroid tapering until discontinuation, Japanese treatment guidelines for AIP recommend a 2–4-week course of prednisolon with 0.6 mg/kg bodyweight, gradual taper of 5 mg per 2 weeks, and maintenance at 2.5–5 mg for up to 3 years.⁴² It turns out that maintenance treatment with low-dose steroids can decrease the risk of relapse. In a Japanese study where 82% of patients with AIP type 1 received maintenance steroid therapy, 24% of patients relapsed within 3 years,¹⁹ whereas in 47% of patients in a study from the Mayo Clinic without steroid maintenance symptoms recurred.⁴⁰ With no controlled trial currently being available, the data suggest that maintenance steroids can effectively decrease the risk of relapse in IgG4-related AIP. In case of steroid refractory disease, contraindications for steroids, or intolerable side effects, two reports, from Khosroshahi et al.¹⁰ and Hart et al.⁴¹, have recently shown that immunomodulators (azathioprine, 6-mercaptopurin, mycophenolate mofetil) and the chimeric anti-CD20-antibody rituximab are reasonable alternatives for treatment of IgG4-related disease. With no comparative clinical trial available, the decision to escalate treatment from steroids to immunomodulators or rituximab must be made on an individual case-to-case basis.

Conclusion

IgG4-related disease is an emerging clinical concept that includes a variety of known as well as new clinical entities such as Mikulicz's disease, Riedels thyroiditis, Küttner's tumour, Ormond's disease, or AIP type 1. Organ manifestations can occur simultaneously or metachroneously at multiple locations and typically include diffuse swelling or mass formation. Symptoms vary depending on the respective localization. The diagnosis is made by a combination of typical organ changes on imaging, elevated serum IgG4 levels, and histology. However, exclusion of differential diagnoses with similar clinical appearance such as malignant lymphoma, Sjögren's syndrome, cancer, and Castleman's disease is warranted. Once the diagnosis is established, steroids are the treatment of choice, which usually leads to remission.

Footnotes

Funding

This work was supported by Alfried-Krupp-von-Bohlen-und-Hahlbach-Stiftung (Graduate Schools Tumour Biology and Free Radical Biology), the Deutsche Krebshilfe/Dr Mildred-Scheel-Stiftung (109102), the Deutsche Forschungsgemeinschaft (DFG GRK840-E3/E4, MA 4115/1-2/3, NI 1297/1-1), the Federal Ministry of Education and Research (BMBF GANI-MED 03152061A and BMBF 0314107), and the European Union (EU-FP-7: EPC-TM and EU-FP7-REGPOT-2010-1).

References

Kamisawa

Funata

Hayashi

. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis. Gut 2003; 52: 683–687.

Okazaki

Umehara

. Are classification criteria for IgG4-RD now possible? The concept of IgG4-related disease and proposal of comprehensive diagnostic criteria in Japan. Int J Rheumatol 2012; 2012: 357071–357071.

Khosroshahi

Stone

. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23: 57–66.

Uchida

Masamune

Shimosegawa

. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012; 2012: 358371–358371.

Umehara

Okazaki

Masaki

. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol Jpn Rheum Assoc 2012; 22: 1–14.

Van der Neut Kolfschoten

Schuurman

Losen

. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317: 1554–1557.

Stone

Zen

Deshpande

. IgG4-related disease. N Engl J Med 2012; 366: 539–551.

Yamamoto

Takahashi

Shinomura

. Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist. Nat Rev Rheumatol 2013; 10: 148–159.

Okazaki

Uchida

Koyabu

. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011; 46: 277–288.

10.

Khosroshahi

Bloch

Deshpande

. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755–1762.

11.

Ghazale

Chari

Smyrk

. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646–1653.

12.

Shimosegawa

Chari

Frulloni

. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352–358.

13.

Yamamoto

Tabeya

Naishiro

. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol Jpn Rheum Assoc 2012; 22: 419–425.

14.

Kamisawa

Chari

Lerch

. Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut 2013; 62: 1373–1380.

15.

Kamisawa

Chari

Giday

. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas 2011; 40: 809–814.

16.

Pickartz

Mayerle

Lerch

. Autoimmune pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 314–323.

17.

Chari

Kloeppel

Zhang

. Histopathologic and clinical subtypes of autoimmune pancreatitis: the honolulu consensus document. Pancreatol Off J Int Assoc Pancreatol IAP Al 2010; 10: 664–672.

18.

Della Torre

Mattoo

Mahajan

. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 2013; 69: 269–272.

19.

Kamisawa

Shimosegawa

Okazaki

. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504–1507.

20.

Hart

Kamisawa

Brugge

. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62: 1771–1776.

21.

Sahani

Kalva

Farrell

. Autoimmune pancreatitis: imaging features. Radiology 2004; 233: 345–352.

22.

Manfredi

Frulloni

Mantovani

. Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiology 2011; 260: 428–436.

23.

Sugumar

Levy

Kamisawa

. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study. Gut 2011; 60: 666–670.

24.

Nakazawa

Naitoh

Hayashi

. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol 2013; 19: 7661–7670.

25.

Tan

. Extrapancreatic findings of IgG4-related disease. Clin Radiol 2013.

26.

Yada

Kudo

Chung

. Autoimmune hepatitis and immunoglobulin g4-associated autoimmune hepatitis. Dig Dis Basel Switz 2013; 31: 415–420.

27.

Umemura

Zen

Hamano

. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol 2011; 46(Suppl 1): 48–55.

28.

Yamamoto

Takahashi

Sugai

. Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev 2005; 4: 195–200.

29.

Geyer

Ferry

Harris

. Chronic sclerosing sialadenitis (Küttner tumor) is an IgG4-associated disease. Am J Surg Pathol 2010; 34: 202–210.

30.

Dahlgren

Khosroshahi

Nielsen

. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res 2010; 62: 1312–1318.

31.

Stone

Khosroshahi

Hilgenberg

. IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum 2009; 60: 3139–3145.

32.

Hamano

Kawa

Ochi

. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002; 359: 1403–1404.

33.

Hamano

Kawa

Horiuchi

. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732–738.

34.

Ghazale

Chari

Zhang

. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706–715.

35.

Cheuk

Yuen

HKL

Chan

JKC

. Chronic sclerosing dacryoadenitis: part of the spectrum of IgG4-related Sclerosing disease? Am J Surg Pathol 2007; 31: 643–645.

36.

Deshpande

Gupta

Sainani

. Subclassification of autoimmune pancreatitis: a histologic classification with clinical significance. Am J Surg Pathol 2011; 35: 26–35.

37.

Umehara

Okazaki

Masaki

. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol Jpn Rheum Assoc 2012; 22: 21–30.

38.

Virk

Shinagare

Lauwers

. Tissue IgG4-positive plasma cells in inflammatory bowel disease: a study of 88 treatment-naive biopsies of inflammatory bowel disease. Mod Pathol 2014; 27: 454–459.

39.

Sah

Chari

. Autoimmune pancreatitis: an update on classification, diagnosis, natural history and management. Curr Gastroenterol Rep 2012; 14: 95–105.

40.

Sah

Chari

Pannala

. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139: 140–148. quiz e12–13).

41.

Hart

Topazian

Witzig

. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2012; 62: 1607–1615.

42.

Kamisawa

Okazaki

Kawa

. Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45: 471–477.

IgG4-related disease: a new kid on the block or an old aquaintance?

Abstract

Keywords

Introduction

Pathogenesis of IgG4-related disease

Clinical presentation

Histological features

Diagnostic criteria

Treatment

Conclusion

Footnotes

Funding

References